Core Viewpoint - PMGC Holdings Inc. will implement a 1-for-7 reverse stock split effective March 10, 2025, to comply with Nasdaq listing requirements and enhance its market presence [1][3]. Group 1: Purpose and Compliance - The reverse stock split is essential for PMGC to meet Nasdaq's listing requirements, thereby maintaining its visibility and investor confidence [3]. - Recent Nasdaq rule changes necessitate this action to ensure compliance, particularly regarding maintaining a stable share price above the minimum threshold [4]. Group 2: Impact on Shareholders - Every 7 shares of common stock will consolidate into one share automatically, with no action required from shareholders [7]. - Fractional shares will be rounded up to one full share, and the trading symbol will remain "ELAB" with a new CUSIP number assigned [7]. - Adjustments will be made to outstanding stock awards, options, and warrants to reflect the reverse split [7]. Group 3: Post-Split Structure - After the split, approximately 577,000 shares of common stock will be issued and outstanding [9]. - The total number of authorized shares will also decrease at the same 1-for-7 ratio, eliminating the need for shareholder approval [9].

Core Insights - PMGC Holdings Inc. has announced its annual sponsorship of TCA Venture Group's Orange County network for 2025, aiming to enhance its investment and M&A opportunities while supporting local business growth [1][5] - TCA Venture Group is recognized as one of the largest and most active angel investor networks in the U.S., having invested over $300 million in more than 525 companies since its inception in 1997 [2][4] - The collaboration with TCA is expected to provide PMGC with access to a vast network of over 400 seasoned investors and industry professionals, enhancing its acquisition strategy and portfolio expansion [4][5] Company Overview - PMGC Holdings Inc. is a diversified holding company managing a portfolio through strategic acquisitions and investments across various industries, currently comprising three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [6] - Northstrive Biosciences Inc. focuses on developing aesthetic medicines, particularly addressing obesity through innovative probiotic approaches [7] - PMGC Research Inc. is engaged in R&D, leveraging Canadian research grants to accelerate scientific discovery [7] - PMGC Capital LLC operates as a multi-strategy investment firm, targeting undervalued companies and assets for sustainable growth [7] TCA Venture Group Overview - TCA Venture Group, formerly known as Tech Coast Angels, has a history of over 25 years in funding early-stage companies across innovation-driven industries, having attracted an additional $2.2 billion in follow-on investments from venture capital firms [2][4] - TCA members provide not only capital but also mentorship, board representation, and strategic partnerships, contributing significantly to the entrepreneurial ecosystem in Southern California [4][8] - TCA has been ranked as the 2 U.S. angel investment network for funded deals and recognized for its network centrality by CB Insights [4]

NEWPORT BEACH, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company,” “PMGC,” “us,” or “we”) (Nasdaq:ELAB), a diversified holding company, today announced an update on its capital structure, highlighting its financial position and ongoing commitment to executing its strategic priorities through its operating subsidiaries. As of February 25, 2025, PMGC’s capital structure is as follows: Common Shares Outstanding: 4,042,295.Stock Options Outstanding: 4,931 shares of Common Stock issuable ...

NorthStrive A PMGC HOLDINGS COMPANY (NASDAQ: ELAB) PIONEERING AESTHETIC MEDICINE DISCLAIMERS & FORWARD LOOKING STATEMENTS Any farward-looling statement made by us is based upan the reasonable judgment of our management at the time such statement is made and speals only as of the date on which it is made. Factors or events that could cousse our actual results to differ may emerge from time to time, and it is not possible for us to predict all of the We undertake no obligation to update any forward-looking st ...

Lead asset EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.Northstrive Biosciences Inc. is preparing the necessary steps to leverage existing EL-22 animal data and human safety studies from Korean licensing partner to arrange an Investigational New Drug filing with the U.S. Food and Drug Administration.EL-32 is a pre-clinical, engineered probiotic expressing dual myostati ...

Core Insights - PMGC Holdings Inc. has initiated strategic investments in fire prevention technology and the U.S. uranium energy market, highlighting its commitment to financing innovation in essential industries with significant growth potential [1][2] Investment Focus - The company believes there is a growing demand for sustainable energy solutions and innovative fire prevention technologies, with investments in uranium exploration supporting nuclear energy as a clean power source to reduce carbon emissions [2] - In the fire prevention sector, PMGC has invested in a U.S.-based company that is developing environmentally friendly technologies aimed at preventing fire ignition and spread, which could provide long-term solutions for saving lives and protecting real estate [3] Portfolio Management - PMGC is dedicated to keeping shareholders informed as its portfolio expands, with a commitment to report any individual investment that exceeds a 4.9% ownership threshold in compliance with SEC regulations [4] - PMGC Capital LLC operates as a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets, aiming to identify high-potential opportunities for sustainable growth and maximizing returns [5] Company Overview - PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries, currently comprising three wholly owned subsidiaries [6]

Groundbreaking research to evaluate the effects of EL-32, alone and in combination with semaglutide, on glycemic control and body composition in diet-induced obese mice.EL-32 is an engineered probiotic expressing dual myostatin & activin-A, focusing on two clinically validated targets that play an important role in regulating muscle. NEWPORT BEACH, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the "Company" or "PMGC") (NASDAQ:ELAB), today announced that its subsid ...

New York, New York, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the completion of the previously announced warrant inducement with existing institutional investors for its client PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the "Company" or "PMGC") (NASDAQ:ELAB), a diversified holding company, for the exercise of certain outstanding Series A warran ...

Warrant Inducement Agreement - PMGC Holdings Inc has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding Series A warrants [1] - The investors agreed to exercise the outstanding warrants to purchase 969,385 shares of the company's common stock at an amended exercise price of $2 00 [1] - The gross proceeds from the exercise of the warrants are expected to be approximately $1 9 million [1] - The closing of the warrant inducement transactions is expected to occur on or about January 28, 2025 [2] New Warrants Issuance - In consideration for the exercise of the warrants, the company agreed to issue new warrants to purchase an aggregate of 969,385 shares of common stock with an exercise price of $2 75 per share [3] - The new warrants are exercisable upon shareholder approval and will expire five years from the date of shareholder approval [3] - The company has agreed to file a registration statement within 30 days with the SEC covering the resale of the shares issuable upon exercise of the new warrants [3] Company Overview - PMGC Holdings Inc is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries [5] - The company's portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc, PMGC Research Inc, and PMGC Capital LLC [5]

Northstrive Biosciences Inc. was invited to present EL-22, a novel myostatin asset aimed at preserving muscle while on weight loss treatments, at the UCLA Obesity Symposium called Anti-Obesity Treatments: Challenges and Emerging Solutions, organized by UCLA Metabolism Theme. This is an invite only event that brings together industry leading voices in the obesity space.NEWPORT BEACH, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: EL ...